Evommune Presents Additional Data From Phase 2a Proof-Of-Concept Trial Of EVO301 In Adults With Atopic Dermatitis At EADV 2026 Congress; Plan To Initiate Subcutaneous Phase 2b Dose-Ranging Trial In Mid-2027

Evommune, Inc. presented additional data from its Phase 2a trial of EVO301 for atopic dermatitis at the EADV 2026 Congress, highlighting its therapeutic signal and favorable safety profile. The trial involved 70 patients and demonstrated comparable efficacy to existing biologics. The company plans to initiate a subcutaneous Phase 2b dose-ranging trial in mid-2027 to further evaluate EVO301's potential.